COMMUNIQUÉS West-GlobeNewswire

NanoNewron Appoints Industry Veteran Marco Taglietti, M.D., as Chief Executive Officer to Lead the Company and the Development of Their Promising Alzheimer’s Compound

04/03/2025 - 21:13

UNION, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- NanoNewron, LLC (“NanoNewron” or the “Company”), a pioneering biotechnology company developing innovative, humanized biologics that cross the blood-brain barrier (BBB) to [...]

BioPorto A/S announces Jens Due Olsen as a Board of Directors candidate intending to appoint Jens Due Olsen as Chair, along with updates on other candidates

04/03/2025 - 21:28

March 4, 2025 Announcement no. 04 BioPorto A/S announces Jens Due Olsen as a Board of Directors candidate intending to appoint Jens Due Olsen as Chair, along with updates on other candidates COPENHAGEN, DENMARK, March 4 [...]

Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025

04/03/2025 - 21:53

Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will host an investor conference call on Thursday, March 6 [...]

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

04/03/2025 - 22:01

SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)- [...]

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

04/03/2025 - 22:01

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today [...]

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

04/03/2025 - 22:01

U.S. FDA approved Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of inflammatory lesions of rosacea in adults in November 2024 [...]

OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

04/03/2025 - 22:05

Record full year 2024 revenue of $204.7 million increased 38% compared to prior year, and more than doubled fourth quarter 2024 adjusted EBITDA WARSAW, Ind., March 04, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“ [...]

BeautyHealth to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025

04/03/2025 - 22:05

LONG BEACH, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announced it will report fourth quarter and full year 2024 financial results [...]

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

04/03/2025 - 22:05

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]

Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36), a Novel Once-Daily Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease

04/03/2025 - 22:05

Statistically significant improvement in primary endpoint (UDysRS total scale) at Week 4 and positive benefit in the key secondary endpoint (UDysRS objective subscale), beginning at Day 7 Favorable tolerability profile [...]

NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results

04/03/2025 - 22:05

-- Record quarterly revenue of $21.5 million in Q4 2024 -- -- Full-year 2025 revenue guidance of $92 to $96 million -- -- Completed an underwritten public offering of $74.8 million, using $49.5 million of the net [...]

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04/03/2025 - 22:05

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly- [...]

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

04/03/2025 - 22:05

IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside [...]

Arvinas to Participate in Upcoming Investor Conferences

04/03/2025 - 22:05

NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that [...]

Teknova Reports Fourth Quarter and Full Year 2024 Financial Results

04/03/2025 - 22:05

Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidance Fourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior year Company provides 2025 revenue [...]

Sanuwave Health to Uplist to the Nasdaq Global Market

04/03/2025 - 22:06

Trading Under the Ticker “SNWV” Expected to Begin on March 7, 2025 EDEN PRAIRIE, Minn., March 04, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the “Company” or "Sanuwave”) (OTCQB: SNWV), a leading provider of next- [...]

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04/03/2025 - 22:07

CHARLESTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

04/03/2025 - 22:15

NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in [...]

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

04/03/2025 - 22:15

THE WOODLANDS, Texas, March 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter and full year 2024 financial results on Thursday, March 6 [...]